Persistence of hepatitis B immune memory until 9–10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months

Figures & data

Figure 1. Participant disposition.

Figure 2. Anti-HBs antibody GMC profile post-primary vaccination, persistence at 12–18 months and 9–10 years of age, and response to HB challenge re-vaccination at 9–10 years of age.

Table 1. Anti-HBs antibody response post-primary vaccination, persistence at 12–18 months and 9–10 years of age, and response to HB challenge re-vaccination at 9–10 years of age.

	DTaP-IPV-HB-PRP∼T and PCV7 primary series				DTaP-IPV-HB/PRP∼T and PCV7 primary series
			9-10 years				9-10 years
	7 months^a	12-18 months	Pre-HB	Post-HB^b	7 months^a	12-18 months	Pre-HB	Post-HB^b
≥10 mIU/mL (%)	99.5 (97.1;100.0)	90.8 (81.0;96.5)	49.3 (37.0;61.6)	92.8 (83.9;97.6)	99.5 (97.1;100.0)	96.5 (87.9;99.6)	42.9 (31.6;54.6)	98.7 (93.0;100)
≥100 mIU/mL (%)	98.4 (95.4;99.7)	72.3 (59.8;82.7)	11.6 (5.14;21.6)	89.9 (80.2;95.8)	99.5 (97.1;100.0)	73.7 (60.3;84.5)	6.5 (2.14;14.5)	97.4 (90.9;99.7)
GMC (mIU/mL)	2477 (2044;3002)	154.5 (107.60;221.79)	13.3 (8.82;20.0)	3692 (1886;7225)	2442 (2096;2844)	162.3 (115.92;227.20)	8.0 (5.93;10.8)	4241 (2763;6507)

Data are % (95% CI) participants with concentration above threshold or geometric mean concentration (GMC) (95% CI); data at 7 months and 9–10 years are from the PP analysis set.

NA, not applicable

^a 1 month after 2, 4, 6 month primary series, coadministered with PCV7 (from Kosalaraksa et al, 2011¹⁵).

^b 1 month post-HB vaccine challenge re-vaccination.

Figure 3. Reverse cumulative distribution curves for anti-HB antibody post-primary vaccination, persistence at 12–18 months and 9–10 years of age, and response to HB challenge re-vaccination at 9–10 years of age.

Figure 4. Individual anti-HBs titer profiles for participants with samples post-primary vaccination and at 9–10 years of age, irrespective of whether a sample was available at 12–18 months of age (top panel: DTaP-IPV-HB-PRP-T + PCV7 [N = 71]; bottom panel: DTaP-IPV-HB//PRP-T + PCV7 [N = 79]).

Kosalaraksa P, Thisyakorn U, Benjaponpitak S, Chokephaibulkit K, Santos-Lima E. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Int J Infect Dis. 2011;15(4):e249–56. doi:10.1016/j.ijid.2010.12.004. PMID:21334243.

 PubMed Web of Science ®Google Scholar